Erbitux Priced For Late Stage Use, ImClone Says; McKesson Is Sole Distributor

The pricing strategy for the oncologic Erbitux reflects the expectation that the biologic will be used primarily in late stage disease, ImClone CEO Daniel Lynch told analysts during a March 15 conference call